Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study

• Main Authors: Mari Yokoi (Author), Atsushi Yonezawa (Author), Daiki Hira (Author), Tomohiro Handa (Author), Kiminobu Tanizawa (Author), Shunsaku Nakagawa (Author), Masahiro Tsuda (Author), Yasuaki Ikemi (Author), Ryo Itotani (Author), Hironori Yoshida (Author), Motoo Nomura (Author), Junichi Matsubara (Author), Kosaku Murakami (Author), Hiroaki Ozasa (Author), Manabu Muto (Author), Tomohiro Terada (Author)
• Format: Book
• Published: BMC, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Interstitial lung disease (ILD) is one of the most common fatal immune-related adverse events (irAEs). ILD development adversely affects the continuation of anticancer drug therapy, including immune checkpoint inhibitor (ICI) therapy and prognosis. There are no established useful...